8.38
+6.08%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lytix Biopharma AS
Its shares trade on Oslo Børs under the ticker LYTIX.OL. It has been listed since 14 June 2021. In the fiscal year to 31 December 2024, it reported revenue of NOK 11.1m and a net loss of NOK 94.3m. At that date it held total assets of NOK 146.5m and shareholders' equity of NOK 107.9m.
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm is involved in development, marketing and sales of pharmaceutical and biotechnology products, as well as related activities. Lytix Biopharma AS developing cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. Lytix Biopharma molecules kill cancer cells, including resistant cells, and expose their internal components to the immune system. This results in uptake of tumor antigens and activation of tumor antigen-presenting cells, thereby generating a broad and long-lasting systemic T-cell response that overcomes tumor heterogeneity. Lytix Biopharma molecules can work in a wide variety of cancer indications and settings, both as mono- and combination therapies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Jun 2021
- Website
- lytixbiopharma.com ↗
Leadership
Pay as last reported
- Mr. Eric FalcandChairman of the Board, since 2025
- Dr. Oystein RekdalChief Executive Officer, Co-Founder, since 2019NOK 4.4m
- Mr. Gjest BreisteinChief Financial Officer
- Dr. Gry StensrudChief Technology Officer
- Dr. Baldur SveinbjornssonChief Scientific Officer
- Dr. Graeme CurrieChief Development Officer
- Mr. Stephen WorsleyChief Business Officer
- Mr. Claus AnderssonDirector
- Ms. Julie Dehaene - PuypeDirector
- Ms. Marie-Louise FjallskogIndependent DirectorNOK 240,000
- Mr. Brynjar ForbergskogIndependent DirectorNOK 240,000
- Dr. Kjetil HestdalIndependent DirectorNOK 240,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lytix Biopharma AS develops novel drugs for resistant bacterial and fungal infections in Health Care sector.
- Lytix Biopharma AS focuses on cancer immunotherapies with broad T-cell response capabilities.
- Lytix Biopharma AS targets resistant cancer cells and tumor heterogeneity with innovative molecules.
Weaknesses
- Lytix Biopharma AS has limited market presence in the Health Care industry.
- Lytix Biopharma AS faces challenges in scaling production of biotechnology products.
- Lytix Biopharma AS lacks established partnerships in the pharmaceutical sector.
Opportunities
- Lytix Biopharma AS can expand into oncology treatments with growing demand.
- Lytix Biopharma AS may leverage Health Care sector growth in Norway.
- Lytix Biopharma AS has potential for international market entry in Europe.
Threats
- Lytix Biopharma AS encounters competition from established biotechnology firms.
- Lytix Biopharma AS faces regulatory hurdles in the Health Care industry.
- Lytix Biopharma AS must navigate high R&D costs in biotechnology development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.